Caribou Biosciences (CRBU) Cash from Financing Activities (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Cash from Financing Activities data on file, last reported at $2.7 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 476.07% year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.0 million (up 49.76% YoY) and the FY2025 annual result came in at $4.8 million, down 71.17% from the prior year.
• Cash from Financing Activities eased to $2.7 million in Q1 2026 per CRBU's latest filing, from $4.1 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $135.1 million in Q3 2023 and bottomed at -$43000.0 in Q4 2023.
• The 5-year median for Cash from Financing Activities is $654000.0 (2022), against an average of $10.6 million.
• Peak annual rise in Cash from Financing Activities reached 20561.77% in 2023, while the deepest fall reached 133.86% in 2023.
• Tracing CRBU's Cash from Financing Activities over 5 years: stood at $127000.0 in 2022, then slumped by 133.86% to -$43000.0 in 2023, then soared by 9083.72% to $3.9 million in 2024, then increased by 5.36% to $4.1 million in 2025, then slumped by 33.76% to $2.7 million in 2026.
• Per Business Quant, the three latest CRBU Cash from Financing Activities figures stand at $2.7 million (Q1 2026), $4.1 million (Q4 2025), and $277000.0 (Q3 2025).

Peer Comparison